Botulinum Toxin Transcutaneous Delivery for Mood Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant therapies for depressive, anxiety, and sleep disorders are associated with severe side effects and marginal efficacy, necessitating the development of new pharmaceuticals that can effectively treat these conditions without causing adverse effects.
Innovation Solution
The use of botulinum toxin compositions administered through non-intracranial routes, such as transcutaneous or subcutaneous injections, to deliver the toxin across the blood-brain barrier, thereby reducing cholinergic neuron transmission and addressing depressive, anxiety, and sleep disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressant medications (monoamine oxidase inhibitors, tricyclic antidepressants, SSRIs) are used to treat depressive, anxiety, and sleep disorders, then some therapeutic effect is achieved, but numerous severe side effects occur including hypertension, headache, myoclonic jerk, sleep disruption, gastrointestinal complications, anticholinergic effects, drowsiness, orthostatic hypotension, cardiac arrhythmias, weight gain, jitteriness, and agitation
Solution Approach 1:
The patent uses botulinum toxin as an intermediary substance that indirectly affects central nervous system neurotransmission. Instead of directly targeting mood-regulating neurotransmitters like traditional antidepressants, botulinum toxin is administered peripherally and exerts its effect through intermediary mechanisms involving cholinergic neuron transmission modulation, thereby achieving therapeutic effects while avoiding the direct side effects of conventional antidepressant medications
Solution Approach 2:
The patent changes the fundamental parameter of treatment approach by shifting from direct central nervous system pharmacological intervention to peripheral neurotoxin administration with central effects. This parameter change involves using botulinum toxin at specific dosages and administration routes (subcutaneous, intramuscular, topical) to modulate cholinergic transmission, thereby achieving mood and sleep disorder treatment with a different side effect profile than traditional antidepressants
2Reliability
If traditional antidepressant medications are used to treat depressive disorders, then some patients experience symptom relief, but the response rate is marginal with only 50-60% showing response and 20-25% absolute difference from placebo
Solution Approach 1:
The patent employs botulinum toxin as an intermediary that modulates cholinergic neuron transmission as a mechanism to improve antidepressant response rates. By targeting acetylcholine release and cholinergic signaling pathways that are implicated in mood regulation, the toxin provides an alternative mechanism of action that may bypass the limitations of traditional antidepressant response rates
Solution Approach 2:
The patent changes the therapeutic parameter by introducing a neurotoxin-based mechanism rather than conventional antidepressant pharmacology. This involves using botulinum toxin's ability to cleave SNARE proteins and inhibit acetylcholine release to modulate neurotransmission in a way that may achieve higher response rates and greater absolute difference from placebo compared to traditional medications
3Object-affected harmful factors
If botulinum toxin is administered to treat depressive, anxiety, and sleep disorders, then safer treatment with fewer side effects is achieved, but the mechanism requires delivery across the blood-brain barrier through non-intracranial routes
Solution Approach 1:
The patent segments the administration approach by using multiple non-intracranial routes (subcutaneous, intramuscular, topical) to deliver botulinum toxin. This segmentation allows the toxin to reach the central nervous system indirectly through peripheral absorption and transport, avoiding the need for direct intracranial injection while achieving the desired central effects with reduced risk
Solution Approach 2:
The patent uses the bloodstream and peripheral nervous system as intermediary pathways to transport botulinum toxin from non-intracranial administration sites to the central nervous system. This intermediary route allows the toxin to cross the blood-brain barrier indirectly and reach target neurons without requiring direct brain injection, thereby simplifying the administration process while maintaining safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a safer and more effective treatment for depressive, anxiety, and sleep disorders by reducing symptoms with fewer adverse effects compared to traditional therapies, while also identifying predictive criteria for patient responsiveness to botulinum toxin treatment.
Implementation Method 1
botulinum toxin neurotoxin for the treatment of depressive and/or sleep disorders as well as other CNS disorders
Data Source
AI summary
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.